A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
- Conditions
- Relapsed Follicular Lymphoma
- Interventions
- Other: ZEVALIN
- Registration Number
- NCT01827605
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Brief Summary
This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab.
- Detailed Description
This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT vs. ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab. Patients with FL will be eligible for screening at the time of relapsed or refractory disease after two or less chemotherapy lines at least one containing rituximab.
This study will be conducted in six steps as follows. Screening Phase, Enrolment and Induction chemotherapy (STEP I) Randomization (STEP II) Stem cell mobilization and collection (STEP III) Consolidation (RIT vs ASCT) (STEP IV) Maintenance (STEP V) Follow-up Phase (STEP VI)
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 159
-
Age 18-65
-
Histologically documented diagnosis of grade I-IIIa FL defined according to WHO guidelines 2008 (Re-biopsy required)
-
Availability of BM and PB for Minimal Residual Disease (MRD) analysis (see Appendix I)
-
Relapsed or refractory disease after ≤ two chemotherapy lines at least one containing Rituximab (Rituximab maintenance is UNOTU considered a therapeutic line)
-
Clinical indication of treatment i.e. Stage II-IV who require therapy according to SIE and GELF criteria (see Appendix II)
-
ECOG performance status 0-2 (unless disease-related) (see Appendix III)
-
Availability of histological material for centralized revision
-
Laboratory values:
- ANC ≥ 1500/mmc unless due to marrow involvement by lymphoma and/or platelets ≥ 100000/mmc unless due to marrow involvement by lymphoma
- Serum creatinine ≤ 1.5 x ULN, unless it is disease related
- Bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN, if patient has Gilbert syndrome)
- AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN if not lymphoma related or ≤ 5.0 x ULN in case of lymphoma liver involvement
-
Adequate cardiac function: LVEF > 50% by echocardiography or MUGA scan
-
Not pregnant or breast-feeding
-
Willingness to use effective contraception during the study and 3 months after the end of treatment
-
No other prior malignancies except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other cancer from which the patient has been disease-free for ≥ 5 years (see Exclusion criteria 14)
-
Signed informed written consent
- Grade IIIb FL, transformed FL or histologies different from FL
- Previous treatment with > two lines of chemotherapy ± rituximab Maintenance is UNOTU considered a therapeutics line)
- Previous ASCT or RIT treatment
- CNS involvement by lymphoma
- HBV positivity with the exception of patients who are seropositive because of hepatitis B virus vaccination and patients HbcAb positive and HbsAg negative with undetectable serum HBV-DNA. Occult carriers: must receive treatment with Lamivudine 100 mg for the duration of treatment program and at least 12 months after treatment cessation; HBV-DNA levels and HBsAg will be monitored every month
- HCV positivity with elevated transaminases or INR or APTT or active virus replication
- HIV positivity
- Any concurrent medical condition requiring long term use (> one month) of systemic corticosteroids
- Active bacterial, viral, or fungal infection requiring systemic therapy
- Any concurrent medical or psychiatric condition which might impair administration of therapy or preclude the ability to give informed consent
- Treatment with an experimental agent within 30 days prior to study entry
- Myelosuppressive chemo or biological therapy within three weeks before study entry (use rituximab course delivered as maintenance is not an exclusion therapy)
- Major surgery other than diagnosis within 4 weeks prior to study entry
- Previous i.v. or i.m. treatments with murine or animal derived antibodies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A RIT ZEVALIN Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures. ARM B ASCT BEAM BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC\>1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance
- Primary Outcome Measures
Name Time Method Progression Free Survival from randomization (rPFS) 36 months PFS will be defined as the time between the date of randomization and the date of disease progression, relapse or death from any cause.
- Secondary Outcome Measures
Name Time Method Overall Survival from randomization (rOS) 36 months OS will be defined as the time between the date of randomization and the date of death from any cause.
Event Free Survival (EFS) 36 months EFS will be measured from the date of randomization to the date of any treatment failure including death, disease progression or relapse, discontinuation of treatment for any reason (toxicity, patient preference, initiation of new treatment without documented progression).
Treatment Free Survival from randomization (TFS) 36 months TFS will be defined as the time between the date of the end of primary treatment until the institution of the next unplanned chemotherapy in randomized population.
Progression Free Survival from enrolment (ePFS) 42 months PFS will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause.
Overall Survival from enrolment (eOS) 42 months OS will be defined as the time between the date of enrolment and the date of death from any cause
Complete Response (CR) Rate At the end of the consolidation phase (6 months) Proportion of CR according to the Cheson 2007 response criteria at the end of consolidation phase.
Overall Response Rate (ORR) At the end of the consolidation phase (6 months) ORR at the end of the consolidation phase is defined as Complete Response (CR) or Partial Response according to the Cheson 2007 response criteria.
Toxicity 42 months Incidence of grade 3 or higher Toxicity measured by CTCAE v.4.03 during therapy.
Molecular Response rate (MR) 36 months Rate of MR will be defined as the proportion of patients achieving PCR negativity after the consolidation phase and during follow up.
Molecular Response rate conversion (cMR) 6 months Rate of conversion will be defined as the proportion of patients with baseline PCR-positivity converting to PCR-negativity during treatment.
Molecular Relapse Rate (MRR) 24 months Rate of molecular relapse will be defined as the proportion of patients with PCR-negativity after treatment converting to PCR-positivity during the first two years of follow-up.
Trial Locations
- Locations (38)
IRCC Onco-Ematologia
🇮🇹Candiolo, Italy
Spedali Civili
🇮🇹Brescia, Italy
Emat Univ - Città della salute e della scienza di Torino
🇮🇹Torino, TO, Italy
Ausl Ravenna
🇮🇹Ravenna, Italy
Presidio Ospedaliero A.Perrino - Divisione di Ematologia
🇮🇹Brindisi, Italy
A.O. SS. Antonio e Biagio e C. Arrigo
🇮🇹Alessandria, Italy
Policlinico Careggi Clinica Ematologica
🇮🇹Firenze, Italy
Istituto Pascale Oncoematologia
🇮🇹Napoli, Italy
SCDU Ematologia - Università del Piemonte Orientale
🇮🇹Novara, Italy
Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona
🇮🇹Verona, VR, Italy
Divisione di Ematologia Osp. Businco
🇮🇹Cagliari, Italy
Ospedale Ferrarotto
🇮🇹Catania, Italy
Policlinico di Modena - Università degli studi
🇮🇹Modena, Italy
Ospedale S. Francesco
🇮🇹Nuoro, Italy
Azienda Ospedaliera V. Cervello
🇮🇹Palermo, Italy
U.O. Complessa di Ematologia Ospedale di Parma
🇮🇹Parma, Italy
Ematologia Policlinico San Matteo
🇮🇹Pavia, Italy
Ospedale Santa Maria della Misericordia
🇮🇹Perugia, Italy
Ospedale Santo Spirito Dipartimento di Ematologia
🇮🇹Pescara, Italy
Unità Ematologia Ospedale Civile di Piacenza
🇮🇹Piacenza, Italy
SC Ematologia Città della salute e della scienza di Torino
🇮🇹Torino, Italy
UO Ematologia Osp. Cardinale Panico
🇮🇹Tricase, Italy
Clinica di Ematologia - A.O.U. S. Maria di Udine
🇮🇹Udine, Italy
A.O.U. San Martino
🇮🇹Genova, GE, Italy
Ematologia, A.O. San Gerardo
🇮🇹Monza, Milano, Italy
A.O. Niguarda
🇮🇹Milano, MI, Italy
Azienda Ospedaliera "Bianchi Melacrino Morelli"
🇮🇹Reggio Calabria, RC, Italy
Ospedale San Bortolo
🇮🇹Vicenza, VI, Italy
Presidio Ospedaliero "A. Tortora"
🇮🇹Pagani, SA, Italy
Clinica di ematologia AOU Umberto I Ospedali Riuniti
🇮🇹Ancona, Italy
Ematologia con Trapianto Policlinico Universitario Consorziale
🇮🇹Bari, Italy
SC Ematologia AO Santa Maria Nuova IRCCS
🇮🇹Reggio Emilia, Italy
IRCCS San Raffaele Unità di Chemioterapia
🇮🇹Milano, Italy
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
A O Papardo
🇮🇹Messina, Italy
Filippo Gherlizoni
🇮🇹Treviso, Italy
Univeristà La Sapienza
🇮🇹Roma, Italy
IRCCS-Centro di riferimento oncologico UO di ematologia e Trapianto Cellule Staminali
🇮🇹Rionero in Vulture, Potenza, Italy